| 발표일자: |
2019년 11월 1일(금)~3(일) |
| 발표번호: |
P(e-poster)-075 |
| 발표장소: |
B3 Parking Area
|
|
|
| 신생혈관성 연령관련 황반변성 환자에서 라니비주맙 치료 후 예후를 예측하는데 있어 안구 방수 내 사이토카인8의 의의 |
| 인제대학교 일산백병원 안과학교실1, 연세대학교 의과대학 안과학교실 시기능개발 연구소2, 건국대학교 의과대학 안과학교실3 |
| 한가희 1, 신주연 1,2, 변석호 2, 정혜원 3, 박진규 2, 이종현 1 |
| 본문 : Purpose: To investigate concentrations of aqueous cytokeratin 8 (CK8) proteins in eyes with neovascular age-related macular degeneration (nAMD) before and during therapy with intravitreal Ranibizumab (IVR) and to identify associations with treatment response.
Methods: Aqueous samples were collected from 40 eyes of 40 patients with treatment naïve nAMD at baseline(day of the first IVR), month 1 (day of the second IVR),and month 2 (day of the third IVR). A group of 47 aqueous samples from 47 patients who underwent cataract surgery without other ocular disease comprised the controls. Main outcome measures were association between baseline CK8 level and treatment response after IVR. Patients were divided by treatment response into responders (when patients showed dry OCT) and non-responders (when patients showed intraretinal or subretinal fluid on OCT) depending on the OCT findings at month 4. Levels of CK8 were determined by commercially available enzyme-linked immunosorbent assay kits.
Results: At the baseline, the mean cytokeratin 8 (CK8) level in the aqueous humor was 8.02 ± 1.11 ng/ml (6.07–12.88), which was significantly higher than that of the control group, 4.93 ± 0.58 ng/ml (p<0.001). The baseline CK8 level was significantly associated with treatment response at month 4 (B=1.861, 95% CI 1.80–22.97, p=0.004). A further evaluation of CK8 as biomarkers was conducted using receiver operating characteristic (ROC) curve analysis. The prediction ability of CK8 estimated by the area under the ROC curve (AUC) was 0.824 (95% CI, 0.683–0.966, p=0.001).
Conclusions: We demonstrated significantly increased concentrations of the CK8 level in the aqueous humor of patients with nAMD compared with the control, and the CK8 level at the baseline was associated with treatment response after IVR. Our results showed that baseline CK8 can be used to discriminate non-responders from responders after intravitreal ranibizumab injections; thus, it can be used as a prognostic factor for the anatomical outcome after IVR. |
| |